Patents by Inventor Julio Alvarez Builla Gomez

Julio Alvarez Builla Gomez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11007199
    Abstract: This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: May 18, 2021
    Assignees: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, University of Alcala De Hernares, South Rampart Pharma, LLC
    Inventors: Nicolas Bazan, Hernan Bazan, Julio Alvarez-Builla Gomez, Dennis Paul, Carolina Burgos Garcia
  • Publication number: 20200323864
    Abstract: Provided are compositions that include a platelet-activating factor antagonist, pharmaceutical compositions including the platelet-activating factor antagonist, methods of treating a modulating the proliferation of a glioma or a pathological condition resulting from patient having a glioma.
    Type: Application
    Filed: January 10, 2020
    Publication date: October 15, 2020
    Inventors: Nicolas G. Bazan, Alberto E. Musto, Julio Alvarez-Builla Gomez
  • Publication number: 20200230087
    Abstract: This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 23, 2020
    Inventors: Nicolas Bazan, Hernan Bazan, Julio Alvarez-Builla Gomez, Dennis Paul, Carolina Burgos Garcia
  • Publication number: 20180104251
    Abstract: Provided are compositions that include a platelet-activating factor antagonist, pharmaceutical compositions including the platelet-activating factor antagonist, methods of treating a modulating the proliferation of a glioma or a pathological condition resulting from patient having a glioma.
    Type: Application
    Filed: March 9, 2016
    Publication date: April 19, 2018
    Inventors: NICOLAS G. BAZAN, ALBERTO E. MUSTO, JULIO ALVAREZ-BUILLA GOMEZ
  • Patent number: 8835466
    Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumors, bacterial, fungal or viral infections, or autoimmune diseases.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: September 16, 2014
    Assignee: Prodimed, S.A.
    Inventors: Julio Álvarez Builla Gómez, José Luis Novella Robisco, Ma Paz Matía Martín, Sonia Serna Pereda
  • Patent number: 7671206
    Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumors, bacterial, fungal or viral infections, or autoimmune diseases.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: March 2, 2010
    Assignee: Prodimed, S.A.
    Inventors: Julio Álvarez Builla Gómez, José Luis Novella Robisco, Ma Paz Matía Martín, Sonia Serna Pereda
  • Patent number: 7662814
    Abstract: New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed, as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: February 16, 2010
    Assignee: Laboratorios Almirall, S.A.
    Inventors: Emma Terricabras Belart, Victor Manuel Segarra Matamoros, Julio Alvarez-Builla Gomez, Juan Jose Vaquero Lopez, Jose Miguel Minguez Ortega
  • Publication number: 20090163555
    Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumours, bacterial, fungal or viral infections, or autoimmune diseases.
    Type: Application
    Filed: April 20, 2007
    Publication date: June 25, 2009
    Applicant: PRODIMED, S.A.
    Inventors: Julio Álvarez Builla Gómez, José Luis Novella Robisco, Ma Paz Matia Martin, Sonia Serna Pereda
  • Publication number: 20090149531
    Abstract: The present invention is a chemical composition including: Use of the compound with the chemical formula can be applied in pharmaceutical compositions for the treatment of psoriasis.
    Type: Application
    Filed: December 10, 2008
    Publication date: June 11, 2009
    Applicant: APOTEKNOS PARA LA PIEL, S.L.
    Inventors: Juan Pablo PIVEL RANIERI, Juan Manuel Ferrer Cuesta, Fernando Martinez Galan, Juan Manuel Irache, Jose Luis Novella Robisco, Juan Jose Perez Rueda, Ma Paz Maria Martin, Julio Alvarez-Builla Gomez, Jaime Bermejo, Fernando Vidal Vanaclocha
  • Publication number: 20070249678
    Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is ?OH, ?ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumours, bacterial, fungal or viral infections, or autoimmune diseases.
    Type: Application
    Filed: April 28, 2006
    Publication date: October 25, 2007
    Applicant: Prodimed, S.A.
    Inventors: Julio Alvarez Builla Gomez, Jose Novella Robisco, Ma Matia Martin, Sonia Serna Pereda
  • Publication number: 20060229306
    Abstract: New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed, as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.
    Type: Application
    Filed: January 23, 2004
    Publication date: October 12, 2006
    Inventors: Emma Terricabras Belart, Victor Segarra Matamoros, Julio Alvarez-Builla Gomez, Juan Vaquero Lopez, Jose Minguez Ortega
  • Patent number: 6987105
    Abstract: A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-?] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: January 17, 2006
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Nicholas G. Bazan, Julio Alvarez Builla Gomez
  • Patent number: 6979682
    Abstract: A novel use of platelet-activating factor antagonists that bind to intracellular PAF binding sites such as BN-50730 (tetrahedra-4,7,8,10 methyl-1 (chloro-1 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4?,3?-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4) has been discovered. These intracellular-binding platelet-activating factor antagonists were found to inhibit both in vivo and in vitro tumor growth and angiogenesis where the angiogenesis is stimulated by basic fibroblast growth factor.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: December 27, 2005
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Jay D. Hunt, Haydee E. Bazan, Victor L. Marcheselli, Julio Alvarez Builla Gomez, Nicholas G. Bazan
  • Publication number: 20030229078
    Abstract: A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-&agr;] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.
    Type: Application
    Filed: March 10, 2003
    Publication date: December 11, 2003
    Inventors: Nicholas G Bazan, Julio Alvarez Builla Gomez
  • Patent number: 6482841
    Abstract: The present invention is concerned with new pyridine double esters of formula (I), their acids, and pharmaceutically acceptable salts. These compounds can be obtained by oxydation of the corresponding 1,4-dihydropyridines, and they are useful as cardioprotective agents in pharmaceutical compositions.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: November 19, 2002
    Assignee: Cermol S.A.
    Inventors: Carlos Sunkel Letelier, Miguel Fau De Casa-Juana Munoz, Julio Alvarez-Builla Gomez, José M. Minguez Ortega, Pierre Statkow, Danielle Straumann, Shyam S. Chatterjee
  • Publication number: 20020169158
    Abstract: A novel use of platelet-activating factor antagonists that bind to intracellular PAF binding sites such as BN-50730 (tetrahedra-4,7,8,10 methyl-1 (chloro-1 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4′,3′-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4) has been discovered. These intracellular-binding platelet-activating factor antagonists were found to inhibit both in vivo and in vitro tumor growth and angiogenesis where the angiogenesis is stimulated by basic fibroblast growth factor.
    Type: Application
    Filed: February 25, 2002
    Publication date: November 14, 2002
    Inventors: Jay D. Hunt, Haydee E. Bazan, Victor L. Marcheselli, Julio Alvarez Builla Gomez, Nicholas G. Bazan
  • Patent number: 5621110
    Abstract: The present invention relates to a series of new N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group of formula I: ##STR1## in which n is a number from 1 to 5, and to processes for preparing these derivatives and to pharmaceutical compositions containing said derivatives; these compounds possess high analgesic activity free from antipyretic activity, and they display little hepatotoxic effect.
    Type: Grant
    Filed: September 18, 1995
    Date of Patent: April 15, 1997
    Assignee: LSU Medical Center Foundation
    Inventors: Nicolas G. Bazan, Julio Alvarez-Builla Gomez
  • Patent number: 5554636
    Abstract: The present invention relates to a series of new N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group, of formula I: ##STR1## in which n is a number from 1 to 5, and to processes for preparing these derivatives and to pharmaceutical compositions containing said derivatives; these compounds possess high analgesic activity free from antipyretic activity, and they display little hepatotoxic effect.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 10, 1996
    Assignee: LSU Medical Center Foundation
    Inventors: Nicolas G. Bazan, Julio Alvarez-Builla Gomez